MedTrace Logo

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

NCT07122700 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-08-14

No results posted yet for this study

Summary

The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.

Conditions

  • Metabolic Associated Fatty Liver Disease
  • Metabolic Associated Steatotic Liver Disease
  • Cirrhosis, Liver
  • NASH
  • Liver Fibrosis
  • Liver Fat
  • Liver Steatoses
  • Liver Inflammation

Sponsors & Collaborators

Principal Investigators

  • Arun Sanyal · Virginia Commonwealth University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-13
Primary Completion
2026-06-30
Completion
2026-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07122700 on ClinicalTrials.gov